Toward personalized medicine with anti-TNF? Not yet . . . (notice n° 1718854)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01087cam a2200169 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260322001915.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Roblin, Xavier |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Toward personalized medicine with anti-TNF? Not yet . . . |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 36 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | There is a link between the presence of the HLA DQA1-05 allele and the development of anti-TNF antibodies. Testing for the HLA DQA1-05 variant makes it possible to isolate patients with a high immunogenic risk under anti-TNF therapy, but its sensitivity and specificity are insufficient to propose precise algorithms based on the results. This test, therefore, remains a decision-support tool. Elevated IFX clearance identifies the patients at greatest risk of requiring a colectomy to treat severe acute colitis. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Barrau, Mathilde |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 31 | 1 | 2024-01-01 | p. 29-32 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2024-1-page-29?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2024-1-page-29?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux